Financial Report: Merck

Merck

3Q Revenues: $10.6 billion  (-4%)

3Q Earnings: $842 million (-27%)

YTD Revenues: $31.8 billion (-3%)

YTD Earnings: $4.6 billion (+24%)

Comments: Pharmaceutical sales were $9.1 billion in the quarter, down 4%. JANUVIA/JANUMET sales were up 5% to $1.4 billion. REMICADE sales were up 5% to $604 million. ZETIA/VYTORIN sales were down 3% to $1.0 billion. GARDASIL were down 11% to $590 million. NASONEX and SINGULAIR sales were down 12% and 22% to $261 million and $218 million, respectively. Consumer Care sales were down 9% to $401 million in the quarter. Results include $425 million of lower sales due to divestitures and the termination of the joint venture with AstraZeneca.